|Title||PharmAbcine, Olinvacimb, able to manage the first recruitment of patients for phase II clinical trial|
PharmAbcine’s Olinvacimb, able to manage the first recruitment of patients for phase II clinical trial
Ÿ Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia
Ÿ While bevacizumab particularly blocks the signaling activated by VEGF-A, Olinvacimab manages to block the signaling activated by VEGF-A, C, and D.
PharmAbcine, a biotech company specialized for developing novel human antibody therapeutics, announced that the company successfully recruited the first patient for phase II clinical trials of olinvacimab (TTAC-0001) in US/Australia as of November 13, 2019.
In the phase II, 36 patients with rGBM (recurrent glioblastoma multiforme), whose tumour is reported to be progressed post the bevacizumab treatment, will be treated with a gradual successive increased dosage of olinvacimab from 16mg/kg, 20mg/kg to 24mg/kg. In this study, safety is the primary endpoint, followed by the assessment of efficacy. The study will also substantiate its effectiveness on patients with respect to Quality of Life through the assessment of tumour and of their reliance on steroid usage.
Gliobloastoma multiforme (GBM) is a type of brain tumour and it represents 15% of brain tumours. Even though there appears to be rigorous attempts to remove the tumour through surgery, chemotherapy and radiotherapy as a means of primary treatments, there is a high proclivity that GBM will likely relapse within a year. Regardless of prudent attentive post-treatment that has been performed for the patients, it is reported that 5 year survival rates are found to be less than 3%
Recently, Roche’s Avastin® (bevacizumab) has been able to gain its top-notch clinical value through the manifestation of remarkable effectiveness in mitigating cerebral edema and consequently it has been approved for medical use in rGBM as a standard treatment. Nevertheless, an issue that starts to arise is that there are non-responding patients to bevacizumab and patients who start to develop non-responsiveness as a consequence of repeated use of bevacizumab. For these individuals,
unmet medical needs for the rGBM indication are quite high owing to the deficient availability of alternative treatments for them.
One of representatives from PharmAbcine said, “There is no current suitable treatment for rGBM patients who are progressed after the bevacizumab treatment and it is unfortunate that it will cause cerebral edema in patients and cause severe damage,” and continued, “We are looking to subjugate other rare diseases that are currently medically unmet and expecting to substantiate prominent asset of olinvacimab. From there we will extend our hands to a bigger spectrum of different indications of cancers.”
Even though they both can mitigate angiogenesis in the TME (tumour microenvironment), onlinvacimb is significantly thought to be a more powerful strategic treatment to impede the process of metastasis and growth of tumour. Notably, while bevacizumab particularly binds to VEGF-A and inhibits the signaling caused by the binding of VEGF-A to VEGFR2, olinvacimab specifically targets VEGFR2 and consequently interferes with the activation of VEGFR2 caused by VEGF-A, C and D.